GlassScriptPhysician profile
Biju Cherian
NPI 1437195369
$3,337.72
in general payments reported to CMS, 2019-2025
28 companies · $734 in 2025
The $734 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $122 · 2021: $551 · 2022: $596 · 2023: $688 · 2024: $248 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.73 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quanta Dialysis Technologies INC | $667.48 | 2021-2022 | |
| Outset Medical INC | $630.13 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $438.86 | 2021-2025 | |
| Nxstage Medical, INC. | $231.51 | 2019-2025 | Nxstage System One, Liberty Select Cycler |
| Baxter Healthcare | $168.03 | 2019-2022 | |
| Akebia Therapeutics INC | $146.95 | 2025 | Vafseo |
| Amgen INC. | $126.41 | 2019-2025 | Tavneos |
| Glaxosmithkline, LLC. | $108.93 | 2022-2025 | Benlysta |
| Alexion Pharmaceuticals, INC. | $101.44 | 2019-2023 | Ultomiris |
| Vifor Pharma, INC. | $96.77 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $71.09 | 2022-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $62.74 | 2022-2024 | |
| Horizon Therapeutics Plc | $61.07 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $56.16 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $55.27 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.87 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $33.30 | 2019 | |
| Mozarc Medical US LLC | $30.57 | 2023 | Chameleon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.65 | 2025 | Jardiance |
| Vantive US Healthcare LLC | $29.25 | 2025 | Renal - Pd |
| Astrazeneca Pharmaceuticals LP | $23.84 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $22.78 | 2019 | |
| Genzyme Corporation | $20.26 | 2019 | |
| Calliditas Therapeutics US INC. | $18.24 | 2024 | |
| Scpharmaceuticals INC. | $17.75 | 2025 | |
| Novo Nordisk INC | $16.40 | 2025 | Ozempic |
| Covidien LP | $14.56 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biju Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.